Search Result

Isoforms Recommended:	ERK2

Results for "

ERK2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ERK (71) 5-HT Receptor (5) Akt (4) AP-1 (2) Apoptosis (10) Autophagy (11) Bombesin Receptor (1) Casein Kinase (1) Caspase (1) CDK (2) COX (3) Dengue Virus (1) DNA/RNA Synthesis (1) Dopamine Receptor (3) DYRK (1) FAK (2) Ferroptosis (1) Flavivirus (1) FLT3 (1) Fluorescent Dye (1) GPR35 (1) GSK-3 (8) HSV (1) Interleukin Related (1) JNK (7) MAPKAPK2 (MK2) (2) MDM-2/p53 (1) MEK (8) Mitochondrial Metabolism (1) Mitosis (2) mTOR (2) Neurotensin Receptor (1) NF-κB (2) Organoid (7) p38 MAPK (3) p62 (1) PARP (2) PD-1/PD-L1 (1) PDGFR (1) PERK (1) PGE synthase (2) PI3K (1) PKC (4) Raf (2) Ras (2) Reactive Oxygen Species (ROS) (1) Reference Standards (10) Small Interfering RNA (siRNA) (3) STAT (1) Trk Receptor (3) VEGFR (1) Wnt (8) β-catenin (7)
By Research Areas:	Cancer (67) Cardiovascular Disease (6) Endocrinology (2) Infection (1) Inflammation/Immunology (15) Metabolic Disease (11) Neurological Disease (9)
Oligonucleotides:	Aptamers (1) Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Phospholipids (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: ERK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10182

Laduviglusib Maximum Cited Publications 295 Publications Verification CHIR-99021; CT99021	Organoid GSK-3 Wnt β-catenin Autophagy	Metabolic Disease Cancer
Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy ^[2] .

HY-50846

SCH772984 180+ Cited Publications	ERK	Cancer
SCH772984 is a highly selective and ATP-competitive *ERK* inhibitor, with IC₅₀s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-na?ve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations .

HY-15816

Ulixertinib 45+ Cited Publications BVD-523; VRT752271	ERK	Cancer
Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of *ERK1/2* kinases, with an IC₅₀ of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line ^[2].

HY-10182B

Laduviglusib trihydrochloride Maximum Cited Publications 295 Publications Verification CHIR-99021 trihydrochloride; CT99021 trihydrochloride	Organoid GSK-3 Wnt β-catenin Autophagy	Cancer
Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib trihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib trihydrochloride induces autophagy ^[2] .

HY-15947

Ravoxertinib 50+ Cited Publications GDC-0994	ERK	Cancer
Ravoxertinib (GDC-0994) is an orally active *ERK* kinase inhibitor with an IC₅₀ of 6.1 nM and 3.1 nM for *ERK1* and *ERK2*, respectively.

HY-101494

Temuterkib 30+ Cited Publications LY3214996	ERK	Cancer
Temuterkib (LY3214996) is a highly selective inhibitor of *ERK1* and *ERK2, with IC₅₀* of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.

HY-10182A

Laduviglusib monohydrochloride Maximum Cited Publications 295 Publications Verification CHIR-99021 monohydrochloride; CT99021 monohydrochloride	Organoid GSK-3 Wnt β-catenin Autophagy	Cancer
Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy ^[2] .

HY-15816A

Ulixertinib hydrochloride 45+ Cited Publications BVD-523 hydrochloride; VRT752271 hydrochloride	ERK	Cancer
Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of *ERK1/2* kinases, with an IC₅₀ of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line ^[2].

HY-12275

FR 180204 20+ Cited Publications	Flavivirus Dengue Virus ERK Apoptosis	Cancer
FR 180204 is an ATP-competitive and selective *ERK* inhibitor. FR 180204 inhibits *ERK1* and *ERK2* with IC₅₀s of 0.51 μM (K_i=0.31 μM) and 0.33 μM (K_i=0.14 μM), respectively .

HY-13076

CHIR-98014 5+ Cited Publications	GSK-3	Metabolic Disease
CHIR-98014 is a potent, cell-permeable GSK-3 inhibitor with IC₅₀s of 0.65 and 0.58 nM for GSK-3α and GSK-3β, respectively; it shows less potent activities against cdc2 and erk2.

HY-P1342

Prosaptide Tx14(A) 1 Publications Verification		Neurological Disease
Prosaptide Tx14(A), a prosaposin-derived peptide, is a potent GPR37L1 and GPR37 agonist with EC₅₀s of 5 and 7 nM, respectively. Prosaptide Tx14(A) increases both ERK1 and ERK2 phosphorylation in Schwann cells ^[2].

HY-18932

DEL-22379 2 Publications Verification	ERK Apoptosis	Cancer
DEL-22379 is an ERK dimerization Inhibitor. DEL-22379 readily binds to ERK2 with a K_d estimated in the low micromolar range, though binding is detectable even at low nanomolar concentrations. ERK2 dimerization is progressively inhibited with an IC₅₀ of ~0.5 μM.

HY-111483

Tizaterkib 3 Publications Verification AZD0364	ERK	Cancer
Tizaterkib (AZD0364) is a potent and selective *ERK2* inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC₅₀ of 0.6 nM.

HY-108330

AG126 3 Publications Verification Tyrphostin AG126	ERK Mitosis	Inflammation/Immunology
AG126 is a tyrosine kinase inhibitor, can inhibit the phosphorylation of *ERK1* and *ERK2* at 25-50 μM. AG126 can be used in meiosis, mitosis, and postmitotic research ^[2] .

HY-112287

ERK1/2 inhibitor 1 5+ Cited Publications	ERK	Cancer
ERK1/2 inhibitor 1 is a potent, orally bioavailable *ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC₅₀* of 3.0 nM against ERK1 and ERK2, respectively .

HY-131249

MK2-IN-3 4 Publications Verification	MAPKAPK2 (MK2)	Inflammation/Immunology
MK2-IN-3 is a potent and selective inhibitor of **MAPKAP-K2 (MK-2), with an IC₅₀** of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC₅₀s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC₅₀s>200 μM). MK2-IN-3 can reduce TNFα production in both U937 cells and in vivo .

HY-137322

THX-B	Neurotensin Receptor	Neurological Disease Metabolic Disease
THX-B is a potent and non-peptidic p75 ^NTR (neurotrophin receptor p75) antagonist. THX-B can be used in the research of diabetic kidney disease, neurodegenerative and inflammatory disorders ^[2] .

HY-114491

Rineterkib	ERK Raf	Cancer
Rineterkib (compound B) is an orally available *ERK1* and *ERK2* inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF ^[2].

HY-18285

Longdaysin	Wnt Casein Kinase ERK CDK	Cancer
Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and *ERK2* with IC₅₀s of 5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively ^[2].

HY-143212

18:0-22:6 DG 1-Stearoyl-2-docosahexaenoyl-sn-glycerol	Ras p38 MAPK ERK PKC	Metabolic Disease Inflammation/Immunology Cancer
18:0-22:6 DG (1-Stearoyl-2-docosahexaenoyl-sn-glycerol) is a diacylglycerol (DG) that can interact with RasGRP (Ras guanine nucleotide-releasing protein) (K_i = 8.37 μM) and modulate the activation of MAP kinases (such as *ERK1/ERK2), which play a crucial role in cellular signaling processes. 18:0-22:6 DG can also activate protein kinase C* (PKC) isozyme. 18:0-22:6 DG can be used for research of cancer, immunology and metabolic disease ^[2].

HY-N0590

Corynoxeine Maximum Cited Publications 6 Publications Verification	ERK	Cardiovascular Disease
Corynoxeine, isolated from the hook of Uncaria rhynchophylla, is a potent *ERK1/ERK2* inhibitor of key PDGF-BB-induced vascular smooth muscle cells (VSMCs) proliferation.

HY-N1374

Magnolin 2 Publications Verification	ERK	Inflammation/Immunology
Magnolin, a major component of Magnolia liliiflora, inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of *ERK1* and *ERK2* with IC₅₀s of 87 nM and 16.5 nM, respectively.

HY-N6257

Cafestol 2 Publications Verification	ERK PGE synthase COX NF-κB Apoptosis Autophagy AP-1 FAK	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Cafestol is an orally active diterpenoid and an inhibitor of *ERK2. Cafestol has elevated blood lipids, anti-inflammatory, anti-angiogenic and anti-diabetic activities. In addition, Cafestol induces tumor cell apoptosis* and autophagy, which can be used in the study of cancer ^[2] .

HY-10182R

Laduviglusib (Standard) CHIR-99021 (Standard); CT99021 (Standard)	Organoid GSK-3 Autophagy Wnt β-catenin Reference Standards	Cancer
Laduviglusib (Standard) is the analytical standard of Laduviglusib. Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy ^[2] .

HY-14604

Xaliproden hydrochloride 1 Publications Verification SR57746A; SR57746 hydrochloride	5-HT Receptor Dopamine Receptor Trk Receptor PKC ERK Akt JNK	Neurological Disease Metabolic Disease
Xaliproden (SR57746) hydrochloride (SR57746A) is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden hydrochloride activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, *ERK1/ERK2, Akt* and p21 Ras/MEK-1 pathways. Xaliproden hydrochloride also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ ³⁵S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden hydrochloride exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden hydrochloride also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden hydrochloride can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety ^[2] .

HY-15947A

Ravoxertinib hydrochloride 50+ Cited Publications GDC-0994 hydrochloride	ERK	Cancer
Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally bioavailable inhibitor selective for *ERK* kinase activity with IC₅₀ of 6.1 nM and 3.1 nM for *ERK1* and *ERK2*, respectively.

HY-P10953

Fulipiftide PSP 29-mer, anti-inflammatory peptide	ERK STAT	Inflammation/Immunology
Fulipiftide is a short peptide derived from pigment epithelium-derived factor (PEDF). Fulipiftide induces the expansion of nuclear stem cell factor ⁺TSPC by activating *ERK2* and STAT3 signaling pathways. Fulipiftide has anti-inflammatory activity and can be used in the study of acute tendon injury ^[2].

HY-113041

Prostaglandin A2 PGA2; Medullin	Apoptosis Caspase PARP ERK MDM-2/p53 JNK HSV	Infection Cancer
Prostaglandin A2 (PGA2) is a Cyclopentenone prostaglandin. Prostaglandin A2 induces Caspase-dependent Apoptosis, activates p53. Prostaglandin A2 activates *ERK2* and JNK1/SAPK. Prostaglandin A2 shows antiviral activity against HSV-1. Prostaglandin A2 has anti-tumor effects. Prostaglandin A2 can be used for the research of colorectal cancer, colorectal carcinoma, breast carcinoma, and herpetic keratitis ^[2] .

HY-112457

MK2-IN-3 hydrate 4 Publications Verification	MAPKAPK2 (MK2)	Inflammation/Immunology
MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive **MAPKAP-K2 (MK-2) inhibitor with an IC₅₀** of 8.5 nM.MK2-IN-3 hydrate is exceptional selectivity against MK-3 (IC₅₀=0.21 μM), MK-5 (IC₅₀=0.081 μM), ERK2 (IC₅₀=3.44 μM), MNK1(IC₅₀=5.7 μM) as well as CDK2, JNK2, IKK2, MSK1, and MSK2 .

HY-150700

RLX-33	ERK	Metabolic Disease
RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC₅₀ values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome .

HY-W010907

Pamoic acid disodium 4 Publications Verification	GPR35 ERK	Neurological Disease
Pamoic acid disodium is a potent GPR35 agonist with an EC₅₀ value of 79 nM. Pamoic acid disodium induces GPR35 internalization and activates *ERK1/2* with EC₅₀ values of 22 nM and 65 nM, respectively. Pamoic acid disodium potently recruits β-arrestin2 to GPR35 and has an antinociceptive effect .

HY-121280

ERK2-IN-4	ERK	Cancer
ERK2-IN-4 (Compound 6o) is an effective and selective *ERK2* inhibitor with a K_i of 0.006 μM. ERK2-IN-4 inhibits the ERK signaling pathway and can be used in cancer research .

HY-145702

MAP855	MEK ERK	Cancer
MAP855 is a highly potent, selective, ATP-competitive and orally active *MEK1/2* kinase inhibitor (MEK1 ERK2 cascade IC₅₀=3 nM, pERK EC₅₀=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2 .

HY-161363

ERK2 allosteric-IN-1	ERK	Metabolic Disease Cancer
ERK2 allosteric-IN-1 (compound 1) is a selective and allosteric *ERK2* inhibitor with the IC₅₀ of 11 μM .

HY-100851A

LY-272015 hydrochloride	5-HT Receptor	Cardiovascular Disease
LY-272015 hydrochloride is an orally active, specific 5-HT_2B receptor antagonist. LY-272015 hydrochloride completely inhibits the phosphorylation of ERK2 induced by 5-HT or BW723C86. LY-272015 hydrochloride is antihypertensive in Deoxycorticosterone Acetate (DOCA)-salt-hypertensive rats ^[2].

HY-151367

SHR2415	ERK	Cancer
SHR2415 is a highly potent, selective and orally active *ERK1/2* inhibitor. SHR2415 has inhibition activity for ERK1 and ERK2 with IC₅₀ values of 2.8 nM and 5.9 nM, respectively. SHR2415 exhibits high potency with an IC₅₀ value of 44.6 nM in Colo205 cells. SHR2415 can be used for the research of cancer .

HY-15816R

Ulixertinib (Standard) BVD-523 (Standard); VRT752271 (Standard)	ERK Reference Standards	Cancer
Ulixertinib (Standard) is the analytical standard of Ulixertinib. This product is intended for research and analytical applications. Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line ^[2].

HY-142433

ERK1/2 inhibitor 7	ERK	Cancer
ERK1/2 inhibitor 7 is a potent *ERK* inhibitor with an IC₅₀ of 0.94 nM for ERK2 (WO2021110168A1, WX006) .

HY-112300

ERK2 IN-1	ERK	Cancer
ERK2 IN-1 is a selective *ERK2* inhibitor with an IC₅₀ of 7 nM .

HY-103544

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P	JNK Interleukin Related Bombesin Receptor	Inflammation/Immunology Cancer
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8 and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca ²⁺ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a bombesin antagonist, and inhibits the growth of small cell lung cancer ^[2]

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Cancer
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively ^[2].

HY-161462

ERK2/p38α MAPK-IN-1	ERK p38 MAPK	Cancer
ERK2/p38α MAPK-IN-1 (Compound 1, In silico Hit-2) is a potent and selective *ERK2* and p38α MAPK inhibitor, with an IC₅₀ of 82 μM for ERK2. ERK2/p38α MAPK-IN-1 binds to the allosteric site of ERK2 and p38α MAPK in distinct manners. ERK2/p38α MAPK-IN-1 can be used for the research of type 2 diabetes .

HY-113592

ERK-IN-4 1 Publications Verification	ERK	Cancer
ERK-IN-4 is an *ERK* inhibitor binds preferentially to ERK2 with a K_d of 5 μM. ERK-IN-4 specificity inhibits ERK Rsk-1 and Elk-1 phosphorylation. ERK-IN-4 has little effect on ERK protein phosphorylation by its upstream activator MEK1/2 .

HY-170879

JD123	p38 MAPK JNK	Cancer
JD123 inhibits JNK1 activity and the expression of cJun (1-135). JD123 is a ATP-competitive p38-γ MAPK inhibitor, but not effect to ERK1, ERK2, or p38-α, p38-β or p38-δ. .

HY-10182C

Laduviglusib dihydrochloride CHIR-99021 dihydrochloride; CT99021 dihydrochloride	GSK-3 β-catenin Wnt Autophagy Organoid	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Laduviglusib dihydrochloride (CHIR-99021 dihydrochloride; CT99021 dihydrochloride) is a potent, selective and orally active GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib dihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib dihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib dihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib dihydrochloride induces autophagy ^[2] .

HY-170526

ERK2 IN-5	ERK JNK	Cancer
ERK2 IN-5 (Compound 5g) is an inhibitor for *ERK2, and exhibits good affinity to ERK2* and JNK3 with K_i of 86 and 550 nM .

HY-P4133

MEK1 Derived Peptide Inhibitor 1	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of *ERK2* by MEK1 with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable .

HY-111407B

(R)-MK-8353 (R)-SCH900353	ERK	Cancer
(R)-MK-8353 ((R)-SCH900353) is the R-enantiomer of MK-8353 (HY-111407). MK-8353 (SCH900353) is a potent, selective and orally active ERK1 and ERK2 inhibitor with IC₅₀s of 23.0 nM and 8.8 nM, respectively .

HY-133084A

ERK-IN-2 free base	ERK	Cancer
ERK-IN-2 free base is a *ERK2* inhibitor with an IC₅₀ value of 1.8 nM. ERK-IN-2 free base might lead to off-target toxicity and/or off-target activity at dose >10 μM .

HY-177132

Sonvuterkib WX001	ERK	Cancer
Sonvuterkib (WX001) is a potent and orally active extracellular signal-regulated kinases (ERK) inhibitor with IC₅₀ values of 1.4, 0.54 nM for ERK1, ERK2, respectively. Sonvuterkib inhibits cell proliferation. Sonvuterkib shows anticancer activity ^[2].

Cat. No.	Product Name	Type

HY-143212

18:0-22:6 DG

1-Stearoyl-2-docosahexaenoyl-sn-glycerol

Biochemical Assay Reagents

18:0-22:6 DG (1-Stearoyl-2-docosahexaenoyl-sn-glycerol) is a diacylglycerol (DG) that can interact with RasGRP (Ras guanine nucleotide-releasing protein) (K_i = 8.37 μM) and modulate the activation of MAP kinases (such as ERK1/ERK2), which play a crucial role in cellular signaling processes. 18:0-22:6 DG can also activate protein kinase C (PKC) isozyme. 18:0-22:6 DG can be used for research of cancer, immunology and metabolic disease ^[2].

Cat. No.	Product Name	Target	Research Area

HY-P1342

Prosaptide Tx14(A) 1 Publications Verification		Neurological Disease
Prosaptide Tx14(A), a prosaposin-derived peptide, is a potent GPR37L1 and GPR37 agonist with EC₅₀s of 5 and 7 nM, respectively. Prosaptide Tx14(A) increases both ERK1 and ERK2 phosphorylation in Schwann cells ^[2].

HY-P10953

Fulipiftide PSP 29-mer, anti-inflammatory peptide	ERK STAT	Inflammation/Immunology
Fulipiftide is a short peptide derived from pigment epithelium-derived factor (PEDF). Fulipiftide induces the expansion of nuclear stem cell factor ⁺TSPC by activating *ERK2* and STAT3 signaling pathways. Fulipiftide has anti-inflammatory activity and can be used in the study of acute tendon injury ^[2].

HY-103544

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P	JNK Interleukin Related Bombesin Receptor	Inflammation/Immunology Cancer
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8 and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca ²⁺ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a bombesin antagonist, and inhibits the growth of small cell lung cancer ^[2]

HY-P5507

ERK2 Substrate ERKtide	Peptides	Others
ERK2 Substrate (Erktide) is a biological active peptide. (Erktide is a peptide substrate for ERK2 (extracellular regulated protein kinase 2) whose activity is regulated by mitogenic stimuli.)

HY-P4133

MEK1 Derived Peptide Inhibitor 1	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of *ERK2* by MEK1 with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable .

HY-P10421

PKCδ substrate	ERK	Cancer
PKCδ substrate acts as a nuclear transporter of *ERK2* and is involved in *ERK2* mediated gene activation. PKCδ is involved in the regulation of cell growth, proliferation, cell cycle arrest, and apoptosis by phosphorylating hBVR and other proteins. PKCδ substrate can be used to study the development of diseases, especially cancer biology .

HY-P5440

ERKtide	ERK	Others
ERKtide is a biological active peptide. (ERKtide is a peptide substrate for ERK2. Extracellular regulated protein kinase 2 (ERK2) is a eukaryotic protein kinase whose activity is regulated by mitogenic stimuli.)

HY-P1342A

Prosaptide Tx14(A) TFA	ERK	Neurological Disease
Prosaptide Tx14(A) TFA, a prosaposin-derived peptide, is a potent GPR37L1 and GPR37 agonist with EC₅₀s of 5 and 7 nM, respectively. Prosaptide Tx14(A) TFA increases both ERK1 and ERK2 phosphorylation in Schwann cells ^[2].

HY-P3992

5-FAM-Dyrktide	Fluorescent Dye DYRK	Others
5-FAM-Dyrktide is a 5-FAM labeled Dyrktide. Dyrktide, a substrate, is efficiently phosphorylated by DYRK1A (K_m=35 μM) but not by ERK2 ^[2].

HY-P3963

Thymus Factor	ERK	Inflammation/Immunology
Thymus Factor (Thymulin) is a key factor responsible for the maturation of humoral immunological faculty . Thymulin is an inhibitor of *ERK* .

HY-P10074

TAT-MEK1	ERK	Inflammation/Immunology
TAT-MEK1 is an inhibitor ofERK2, consisting of TAT and MEK1 (N-terminal), TAT (YGRKKRRQRRR) derived from human immunodeficiency (HIV-1) transcriptional trans activator (TAT), is a cell-penetrating peptide. TAT-MEK1 IC₅₀ in vitro for ERK2 is 29 μM ^[2].

Species:	Human (3)
Tag:	His (1) GST (1) Flag (1)
Source:	Sf9 insect cells (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P704008

	*MAPK1/ERK2* Protein, Human (Inactive, GST)** MAPK1; mitogen-activated protein kinase 1; PRKM1, PRKM2; ERK; ERK2; MAPK2; p41mapk; ERK-2; MAPK 2; p42-MAPK; MAP kinase 1; MAP kinase 2; MAP kinase isoform p42; protein tyrosine kinase ERK2; mitogen-activated protein kinase 2; extracellular signal-regulated kinase 2; p38; p40; p41; ERT1; PRKM1; PRKM2; P42MAPK	Human	E. coli
	ERK2 Protein, a key component of the MAPK/ERK cascade, regulates diverse cellular processes such as transcription, translation, mitosis, apoptosis, endosomal dynamics, and Golgi apparatus fragmentation. Through phosphorylation, it modulates substrates including transcription factors, cytoskeletal elements, apoptosis regulators, translation regulators, protein kinases, and phosphatases. MAPK1/ERK2 Protein, Human (Inactive, GST) is the recombinant human-derived MAPK1/ERK2 protein, expressed by E. coli, with N-GST labeled tag.

HY-P702735

	*MAPK1/ERK2* Protein, Human (Active, Flag-His)** MAPK1; mitogen-activated protein kinase 1; PRKM1, PRKM2; ERK; ERK2; MAPK2; p41mapk; ERK-2; MAPK 2; p42-MAPK; MAP kinase 1; MAP kinase 2; MAP kinase isoform p42; protein tyrosine kinase ERK2; mitogen-activated protein kinase 2; extracellular signal-regulated kinase 2; p38; p40; p41; ERT1; PRKM1; PRKM2; P42MAPK	Human	E. coli
	ERK2 Protein, a key component of the MAPK/ERK cascade, regulates diverse cellular processes such as transcription, translation, mitosis, apoptosis, endosomal dynamics, and Golgi apparatus fragmentation. Through phosphorylation, it modulates substrates including transcription factors, cytoskeletal elements, apoptosis regulators, translation regulators, protein kinases, and phosphatases. MAPK1 Protein, Human (Active, Flag, His) is the recombinant human-derived MAPK1, expressed by E. coli, with N-His, N-Flag labeled tag.

HY-P75223

	*MAPK1/ERK2* Protein, Human (Active, sf9, His)** 1 Publications Verification Mitogen-activated protein kinase 1; MAPK 1; ERT1; ERK-2; p42-MAPK	Human	Sf9 insect cells
	ERK2 Protein, a key component of the MAPK/ERK cascade, regulates diverse cellular processes such as transcription, translation, mitosis, apoptosis, endosomal dynamics, and Golgi apparatus fragmentation. Through phosphorylation, it modulates substrates including transcription factors, cytoskeletal elements, apoptosis regulators, translation regulators, protein kinases, and phosphatases. MAPK1/ERK2 Protein, Human (sf9, His) is the recombinant human-derived ERK2 protein, expressed by Sf9 insect cells , with C-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (6) Rabbit (5)
Reactivity:	Human (11) Rat (5) Mouse (11) Monkey (2) Rabbit (2)
Application:	IHC-P (8) ICC/IF (10) IF-Tissue (2) IP (2) IHC-F (2) WB (11) FC (6) ELISA (6)
Isotype:	IgG (6) IgG2a (2) IgG2b (2)
Conjugation:	Non-conjugated (11)
Clonality:	Polyclonal (1) Monoclonal (6) Recombinant (2)
Modification:	Phosphorylated (2) Unmodified (6)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80394

	ERK2 Antibody (YA452)	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse, Rat
	ERK2 Antibody (YA452) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ERK2.

HY-P85835

	ERK2 Antibody (YA5527) MAPK1; ERK2; PRKM1; PRKM2; Mitogen-activated protein kinase 1; MAP kinase 1; MAPK 1; ERT1; Extracellular signal-regulated kinase 2; ERK-2; MAP kinase isoform p42; p42-MAPK; Mitogen-activated protein kinase 2; MAP kinase 2; MAPK 2	WB, ICC/IF, ELISA	Human, Mouse, Rat
	ERK2 Antibody (YA5527) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to ERK2.

HY-P85629

	*Phospho-ERK1/2(Thr202/Tyr204) Antibody (YA5321)* ERK 1; ERK 2; ERK-2; ERK1; ERK1/2; ERK2; ERT1; ERT2; Extracellular signal regulated kinase 1; Extracellular signal regulated kinase 1	WB	Human, Mouse
	Phospho-ERK1/2(Thr202/Tyr204) Antibody (YA5321) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Phospho-ERK1/2(Erk1/2)(Thr202/Tyr204).

HY-P81156

	*phospho-ERK1 + 2 (Thr183/Tyr185) Antibody* ERK1 + ERK2 (phospho Thr183/Tyr185); phospho-ERK1/MAPK-1/2(Thr183/Tyr185); ERK 1; ERK 2; ERK-2; ERK1; ERK2; ERT1; ERT2; Extracellular signal regulated kinase 1; Extracellular signal regulated kinase 1; Extracellular signal regulated kinase 2; Extracellular signal regulated kinase 2; Extracellular signal-regulated kinase 2; HS44KDAP; HUMKER1A; Insulin stimulated MAP2 kinase; MAP kinase 1; MAP kinase 2; MAP kinase isoform p42;	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human, Mouse
	phospho-ERK1 + 2 (Thr183/Tyr185) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to phospho-ERK1 + 2 (Thr183/Tyr185).

HY-P84237

	ERK1/2 Antibody (YA3934) ERK; p38; p40; p41; ERK2; ERT1; MAPK2; PRKM1; PRKM2; P42MAPK; p41mapk; MAPK1	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse, Rabbit
	ERK1/2 Antibody (YA3934) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to ERK1/2.

HY-P84237A

	ERK1/2 Antibody (YA3934)(PBS only) ERK; p38; p40; p41; ERK2; ERT1; MAPK2; PRKM1; PRKM2; P42MAPK; p41mapk; MAPK1	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse, Rabbit
	ERK1/2 Antibody (YA3934) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to ERK1/2.

HY-P84236

	ERK2 Antibody (YA3933) ERK; p38; p40; p41; ERT1; MAPK2; PRKM1; P42MAPK; p41mapk; MAPK1	WB, IHC-P, ICC/IF, ELISA	Human, Mouse, Monkey
	ERK2 Antibody (YA3933) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to ERK2.

HY-P80393

	ERK1/2 Antibody (YA453) 4 Publications Verification MAP kinase 3; MAPK 3; ERK-1; p44-MAPK; MAP kinase 1; MAPK 1; ERK-2; p42-MAPK	WB, ICC/IF, IP, FC	Human, Mouse, Rat
	ERK1/2 Antibody (YA453) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ERK1/2.

HY-P84236A

	ERK2 Antibody (YA3933)(PBS only) ERK; p38; p40; p41; ERT1; MAPK2; PRKM1; P42MAPK; p41mapk; MAPK1	WB, IHC-P, ICC/IF, ELISA	Human, Mouse, Monkey
	ERK2 Antibody (YA3933) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to ERK2.

HY-P86654

	ERK1/2 Antibody (YA6346) ERK1+ERK2; ERK 1; ERK 2; ERK-2; ERK1; ERK2; ERT1; ERT2; Extracellular signal regulated kinase 1; Extracellular signal regulated kinase 2; Extracellular signal-regulated kinase 2; HS44KDAP; HUMKER1A; Insulin stimulated MAP2 kinase; MAP kinase 1; MAP kinase 2; MAP kinase isoform p42; MAP kinase isoform p44; MAPK 1; MAPK 2; MAPK 3; MAPK1; MAPK2; MAPK3; MGC20180; Microtubule associated protein 2 kinase; Mitogen activated protein kinase 1; Mitogen activated protein kinase 2; Mitogen activated protein kinase 3; Mitogen-activated protein kinase 1; Mitogen-activated protein kinase 2; MK01_HUMAN; MK03_HUMAN; p38; p40; p41; p41mapk; p42 MAPK; p42-MAPK; p42MAPK; p44 ERK1; p44 MAPK; p44ERK1; p44MAPK; PRKM 1; PRKM 2; PRKM 3; PRKM1; PRKM2; PRKM3; Protein kinase mitogen activated 1; Protein kinase mitogen activated 2; Protein kinase mitogen activated 3; Protein tyrosine kinase ERK 2.	WB, IHC-P, IHC-F, ICC/IF, IF-Tissue, FC	Human, Mouse, Rat
	ERK1/2 Antibody (YA6346) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ERK1/2.

HY-P810604

	*Phospho-Erk1 (Thr202)+Erk2* (Thr185) Antibody (YA9866)** ERK1; PRKM3; P44ERK1; P44MAPK; HS44KDAP; HUMKER1A; MGC20180	WB, ICC/IF, IHC-P, FC, IF-Tissue	Human, Mouse, Rat
	Phospho-Erk1 (Thr202)+Erk2 (Thr185) Antibody (YA9866) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-Erk1 (Thr202)+Erk2 (Thr185).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-143212

18:0-22:6 DG 1-Stearoyl-2-docosahexaenoyl-sn-glycerol		Phospholipids
18:0-22:6 DG (1-Stearoyl-2-docosahexaenoyl-sn-glycerol) is a diacylglycerol (DG) that can interact with RasGRP (Ras guanine nucleotide-releasing protein) (K_i = 8.37 μM) and modulate the activation of MAP kinases (such as *ERK1/ERK2), which play a crucial role in cellular signaling processes. 18:0-22:6 DG can also activate protein kinase C* (PKC) isozyme. 18:0-22:6 DG can be used for research of cancer, immunology and metabolic disease ^[2].

HY-177802

C3 sodium		Aptamers
C3 sodium is an aptamer that binds to Erk2. C3 binds to the MAP kinase insert domain, a unique site on Erk1/2. Due to this recognition profile C3 inhibits Erk2 activation by its upstream kinase MKK1.

HY-RS08094

Mapk1 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Mapk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mapk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS08092

MAPK1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
MAPK1 Human Pre-designed siRNA Set A contains three designed siRNAs for MAPK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS08093

Mapk1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Mapk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mapk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

ERK2

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Antibodies

Oligonucleotides

Natural
Products